Ann: EU Medical Cannabis License Granted with Strategic Agreement, page-2

European Medical Cannabis License Granted Under New Strategic Research Collaboration

• Strategic research agreement signed with University of Ljubljana, who have been issued a full medical cannabis licenses for a MXC breeding and cultivation program

• The goal of the research program is to create medicinal cannabis strains tailored for specific medical indications, including epilepsy, chronic pain, as well as the side effects of oncology

• Will produce critical new genetic intellectual property for MGC Pharmaceuticals, giving it a strong competitive advantage for future production operations

• Research program aims to create medicinal cannabis strains tailored for specific medical indications, by: o Developing new, improved varieties of medicinal cannabis via cross breeding from MGC Pharmaceuticals’ proprietary strains o Developing fast and efficient cannabis breeding methods

• Program to be run at the Biotechnical Faculty and led by Jana Murovec, PhD, in collaboration with Marko Flajšman, PhD, and the highly-respected Professor Borut Bohanec, PhD, head of the Centre for Plant Biotechnology and Breeding

• Builds the Company’s global medical cannabis genetics and breeding research programs, with its Panax acquisition and operations in the Czech Republic and its recently announced partnership with RMIT in Australia